Active, not recruitingPhase 2NCT07023835
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Studying Amyotrophic Lateral Sclerosis (ALS)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zydus Therapeutics Inc.
- Principal Investigator
- Deven V ParmarZydus Therapeutics Inc.
- Intervention
- 50 mg Usnoflast(drug)
- Enrollment
- 240 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (17)
- Zydus US015, La Jolla, California, United States
- Zydus US008, Orange, California, United States
- Zydus US013, San Francisco, California, United States
- Zydus US005, New Britain, Connecticut, United States
- Zydus US012, Tampa, Florida, United States
- Zydus US007, Atlanta, Georgia, United States
- Zydus US010, Boston, Massachusetts, United States
- Zydus US006, Detroit, Michigan, United States
- Zydus US014, Lincoln, Nebraska, United States
- Zydus US003, Winston-Salem, North Carolina, United States
- Zydus 009, Pittsburgh, Pennsylvania, United States
- Zydus US001, Dallas, Texas, United States
- Zydus US002, Houston, Texas, United States
- Zydus US004, Richmond, Virginia, United States
- Zydus US011, Seattle, Washington, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07023835 on ClinicalTrials.govOther trials for Amyotrophic Lateral Sclerosis (ALS)
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07017946Intestinal Microbiome Transplant in ALSDuke University
- ENROLLING BY INVITATIONNANCT07539662Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT07287397Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALSVector Y Therapeutics
- RECRUITINGNANCT07413718Inspiratory Muscle Training in Amiotrophyc Lateral SclerosisUniversity Ramon Llull
- RECRUITINGPHASE1NCT06665165AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisAmylyx Pharmaceuticals Inc.
- RECRUITINGNANCT06609213Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALSAndrea Charvet
- RECRUITINGNANCT06249412The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS PatientsGroupe Hospitalier du Havre
- RECRUITINGNANCT06834269Transcranial Static Magnetic Stimulation (tSMS) and Potential Theranostic Biomarkers in Amyotrophic Lateral Sclerosis.Campus Bio-Medico University